双苓扶正抗癌制剂对胃癌细胞端粒酶活性及p53蛋白表达的研究  

The Effect of Shuangling Fuzheng Kangai Preparation on Telomerase Activity and p53 Proteins Expression of Human Gastric Cancer Cells

作　　者：陈华圣[1] 陈钢[1] 许爱华[1] 苏庆[1] 贾玲昌[2] 

机构地区：[1]扬州大学医学院,江苏扬州225001 [2]江苏省苏北人民医院,江苏扬州225001

出　　处：《中药材》2006年第12期1326-1329,共4页Journal of Chinese Medicinal Materials

基　　金：江苏省科技厅社会发展基金项目(BS99382);江苏省高校自然科学基础研究项目(No.06KJB360131)

摘　　要：目的:检测双苓扶正抗癌制剂对人胃癌细胞端粒酶活性及p53蛋白表达的影响,探讨该制剂的抗肿瘤作用机制。方法:应用TRAP-PCR-ELISA法检测端粒酶活性;应用免疫组织化学ABC法检测p53蛋白的表达。结果:对照组SGC-7901细胞端粒酶活性为阳性,双苓扶正抗癌制剂(160和320μg/ml)2个给药组其端粒酶活性皆为阴性;对照组SGC-7901细胞的p53蛋白阳性标记率为(41±13)%,双苓扶正抗癌制剂(160和320μg/ml)2个给药组其p53蛋白阳性标记率分别为(15±5)%、(13±6)%。结果显示,双苓扶正抗癌制剂可抑制SGC-7901细胞端粒酶活性及突变型p53蛋白的表达。结论:双苓扶正抗癌制剂抗肿瘤作用机制可能与其抑制端粒酶活性和下调突变型p53蛋白的表达有关。Objective ： To study the influence of Shuangling Fuzheng Kangai Preparation（SLFKP） on telomerase acitvity and p53 proteins expression in human gastric cancer ceils, and discuss the anti-tumor mechanism of SLFKP in vitro. Methods ： The telomerase activity were measured by the techniques of TRAP-PCR-ELISA. The p53 proteins expression level of hunma gastric cancer SGC-7901 cells were measured by the techniques of immunohistochemistry ABC. Results： The telomerase activity of RPMI 1640 control group were positive. The telomerase activity of SLFKP（ 160 and 320 μg/ml,48 h） group all were negative. Rate of positive cells of p53 proteins of RPMI 1640 control group were（41 ± 13） % and that of SLFKP（ 160 and 320 μg/ml,48 h） group were （ 15 ±5 ） % and （ 13 ± 6） %. The results showed that SLFKP could inhibit telomerase activity and the expression level of mutated type p53 proteins of human gastric cancer SGC-7901 cells. Conclusion ： The anti-tumor action mechanism of SLFKP may be relate to its inhibited telomerase activity and down-regulating effect on the expression of p53 proteins of human gastric cancer SGC-7901 cells.

关 键 词：双苓扶正抗癌制剂 胃癌细胞 端粒酶 P53蛋白 

分 类 号：R285.5[医药卫生—中药学]